2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
18 February 2025Portfolio NewsLoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors
10 February 2025Portfolio NewsAdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer- 4 February 2025Portfolio NewsAustralian radiopharma play Advancell taps VCs for $112M in ‘scale capital’
- 3 February 2025Portfolio NewsAdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing
27 January 2025Portfolio NewsHarness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of transformational neurodegeneration pipeline
23 January 2025Portfolio NewsDoctors of Physical Therapy Partners with Empower Physical Therapy, Expanding Services to Arizona, California, Louisiana and Texas- 15 January 2025SV NewsSV Therapeutics 2024 Year in Review
9 January 2025Portfolio NewsAlchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS
26 December 2024SV NewsKate Bingham on innovation in drug development on World at One Radio 4- 19 December 2024SV NewsSV Health Investors Promotes A.J. Rossi to Partner on Healthcare Growth-Buyout Team
- 16 December 2024SV News2024 SV Therapeutics Impact & ESG Report
9 December 2024Portfolio NewsMestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform
